Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Invested Capital: 2012-2025

Historic Invested Capital for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $1.3 billion.

  • Agios Pharmaceuticals' Invested Capital fell 21.05% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 21.05%. This contributed to the annual value of $1.5 billion for FY2024, which is 90.00% up from last year.
  • Agios Pharmaceuticals' Invested Capital amounted to $1.3 billion in Q3 2025, which was down 6.22% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Invested Capital registered a high of $2.3 billion during Q1 2021, and its lowest value of $660.5 million during Q2 2024.
  • For the 3-year period, Agios Pharmaceuticals' Invested Capital averaged around $1.1 billion, with its median value being $1.0 billion (2023).
  • In the last 5 years, Agios Pharmaceuticals' Invested Capital soared by 267.29% in 2021 and then slumped by 47.43% in 2022.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Invested Capital stood at $1.3 billion in 2021, then fell by 14.80% to $1.1 billion in 2022, then fell by 26.33% to $811.0 million in 2023, then surged by 90.00% to $1.5 billion in 2024, then decreased by 21.05% to $1.3 billion in 2025.
  • Its Invested Capital was $1.3 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.5 billion in Q1 2025.